7/19/2024  4:54:24 PM Chg. -2.10 Volume Bid4:55:00 PM Ask4:55:00 PM Market Capitalization Dividend Y. P/E Ratio
151.50DKK -1.37% 39,605
Turnover: 2.24 mill.
-Bid Size: - -Ask Size: - 33.7 bill.DKK - 69.27

Business description

ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy.
 

Management board & Supervisory board

CEO
Carsten Hellmann
Management board
Claus Steensen Sølje, Søren Niegel, Henriette Mersebach
Supervisory board
Anders Hedegaard, Lene Skole, Gitte Aabo, Lars Holmqvist, Jesper Høiland, Bertil Lindmark, Alan Main, Katja Barnkob, Nanna Carlson, Lise Lund Mærkedahl, Johan Smedsrud
 

Company data

Name: ALK-Abelló A/S
Address: Boge Alle 6-8,Horsholm 2970
Phone: (+45) 4574 7576
Fax: (+45) 4574 8690
E-mail: reception@alk-abello.com
Internet: www.alk.net
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: -
End of financial year: 12/31
Free Float: -
IPO date: -

Investor relations

Name: Per Plotnikof
IR phone: +45 4574 7527
IR Fax: -
IR e-mail: ppidk@alk.net

Company calendar

CW 34 | 8/23/2024 Interim Report 2nd Quarter/6 Months
CW 46 | 11/14/2024 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Others
 
54.70%
The Lundbeck Foundation
 
40.30%
The Danish Labour Market Supplementary Pension
 
5.00%